

Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Announces Phase III Clinical Trial Result of TRM-270

TOKYO, April 23, 2025 – ASKA Pharmaceutical Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that the primary endpoint of the Phase III clinical trial for an anti-adhesion absorption barrier agent (development code: TRM-270) being developed jointly with Toray Industries, Inc. (Head Office: Chuo-ku, Tokyo/ President: Mitsuo Ohya; hereinafter “Toray”) has not been achieved.

This study was conducted at multiple medical institutions in Japan with the aim of preventing adhesions following surgical procedures in the gastrointestinal area. It compared the safety and efficacy of TRM-270 with existing standard treatments. However, it was unable to demonstrate statistical non-inferiority in the primary endpoint of “occurrence rate of adhesion in small incisions.”

In response to this, ASKA will proceed with a detailed analysis of the test results and carefully consider the development policy.

The Company is currently assessing the impact of this matter on its business results, and will promptly disclose any material information if necessary.

ASKA will continue to develop innovative products in the medical field and contribute to improving the quality of life of patients.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp